Roche Reports Strong First Quarter Sales Amid Promising Pipeline Developments

Roche Holding AG has reported a remarkable increase in its sales figures for the first quarter of 2025, driven by robust demand for its innovative therapies and a strengthening pipeline of potential new products. The pharmaceutical giant, known for its groundbreaking work in oncology and diagnostics, saw its revenues climb by 11% compared to the same quarter last year, amounting to an impressive CHF 16.5 billion ($18 billion).

Continue reading